Keyword: Kevzara (sarilumab)
Weeks after launching a U.S. trial to evaluate IL-6 inhibitor Kevzara for COVID-19, Sanofi and Regeneron have launched a matching study abroad.
Through weeks of sleepless nights and conference calls, Regeneron's research team is well positioned to solve COVID-19 with regulators' backing.
Chinese authorities already recommend Actemra for COVID-19, but Roche wants to determine its efficacy via a carefully designed clinical study.
With Sanofi and Regeneron testing IL-6 med Kevzara to treat COVID-19, another drug in the class is rolling into testing in an Italian hospital.
Sanofi and Regeron aim to fast track arthritis med Kevzara for use in novel coronavirus patients with an immediate phase 2/3 global clinical program.
Regeneron and Sanofi are the latest drugmakers to explore whether an existing medicine might be able to fight the novel coronavirus.
Amid a restructuring of its partnership with Sanofi for Praluent and Kevzara, Regeneron is planning to lay off 15 New York staffers.
After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.
More than a decade in, Sanofi and Regeneron's antibody partnership has spawned several drugs, but it took Dupixent to fuel its first profit.
Sanofi's CFO search lasted two months and led the company to a financial executive from French automaker PSA Group.